Moderna (MRNA -1.77%) once was one of the stock market's biggest stars. The biotech stock surged more than 400% back in 2020 as it brought a coronavirus vaccine from drawing board to market in less than a year. And it continued to gain as it quickly generated billions of dollars in earnings, thanks to that vaccine.In recent times, though, Moderna's top-selling vaccine has prompted investors to turn away from the stock. That's because, as we head toward a post-pandemic situation, they're worrying about the c ...

The latest trading session saw Moderna (MRNA) ending at $100.35, denoting a -1.77% adjustment from its last day's close. This move lagged the S&P 500's daily loss of 0.56%. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq depreciated by 0.59%.Coming into today, shares of the biotechnology company had gained 14.67% in the past month. In that same time, the Medical sector gained 3.8%, while the S&P 500 gained 1.2%.The upcoming earnings release of Moderna will be of great interest to in ...

Moderna (MRNA) closed the latest trading day at $109.46, indicating a -0.65% change from the previous session's end. The stock's performance was behind the S&P 500's daily gain of 0.57%. Meanwhile, the Dow gained 0.46%, and the Nasdaq, a tech-heavy index, added 0.75%.Prior to today's trading, shares of the biotechnology company had gained 41.18% over the past month. This has outpaced the Medical sector's gain of 6.86% and the S&P 500's gain of 3.4% in that time.The investment community will be paying close ...

Today, identifying investments with promising growth potential is a quest every investor undertakes. Within the loud noises of the stock market, three standout companies are making waves. Their strategies and innovations forecast substantial gains, promising a 2X capital level by 2025.The first one on the list is a pioneer in digital payments, emphasizing enhanced security measures and seamless platform integrations. The second is a pharmaceutical giant. It focuses on an ambitious lineup of new products, di ...

At the J.P. Morgan Healthcare Conference, Moderna (MRNA) announced several financial updates on its business and updates on its pipeline progress.Financial UpdatesFor 2023Moderna reported unaudited/preliminary product sales of nearly $6.7 billion for 2023, which were generated in its entirety from the sales of its mRNA-based COVID-19 vaccine. This figure was in line with the company’s previously reported guidance outlook, wherein it expected full-year vaccine sales to be at least $6 billion.The reported pre ...

Moderna, Inc. (NASDAQ:MRNA) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2024 6:45 PM ET Company Participants Jamey Mock - Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Jessica Fye Great. Welcome, everyone. Good afternoon. Good afternoon. My name is Jessica Fye. I'm a biotech analyst at JPMorgan, and we're continuing the 42nd Annual Healthcare Conference today with Moderna. I'm going to pass it over to the company's CFO, Jamey Mock, for a presentation and then we're ...

Moderna on Monday said 2023 product sales hit $6.7 billion, slightly above the company’s latest guidance for at least $6 billionExternal link, down 63.6%External link from 2022. Sales for 2023 also beat the consensus estimate for $6.3 billion, according to FactSet. ...

Moderna Inc.’s stock MRNA, +2.26% was up by 1.2% after the drug maker said it sold $6.7 billion of products in 2023. Analyst expected the company to sell $6.35 billion in products in 2023. Moderna said its share of the U.S. COVID-19 drug market was 48% in 2023, up from 37% in 2022. It also continues to expect 2024 product sales of approximately $4 billion, compared to the analyst estimate of $4.4 billion. It continues to expect it will return to sales growth in 2025, and break even in 2026. Moderna is also ...

Moderna on Monday said its Covid vaccine sales plunged by about two-thirds in 2023 to $6.7 billion, as fewer people rolled up their sleeves for an updated version of the jab.The revenue from the shots met Moderna's forecast for the year, even as sales plummeted from the more than $18 billion the company booked in 2022. Moderna's announcement, which came ahead of its presentation at the annual JPMorgan Healthcare Conference, shows the steep drop in demand for Covid products last year as cases and public conc ...

Jelena Stanojkovic/iStock via Getty Images At a Glance Delving into Moderna's (NASDAQ:MRNA) trajectory, my earlier analysis shed light on its eclectic project range. This spectrum spans from oncology to infectious diseases, with notable breakthroughs in RSV and flu vaccines. Moderna has since leaped forward, especially with mRNA-1083. This vaccine, both innovative and dual-purpose, targets COVID-19 and flu. It's now in Phase 3, with approval expected in 2025. However, it's not all smooth sailing. The pa ...